Abstract
BackgroundUp to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of response. One explanation is immunogenicity leading...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have